Curious to see your top suppliers emissions?
Book a demo for a pilot project
Lisata Therapeutics, Inc.
Pharmaceutical Preparation ManufacturingUnited States
Last verified 14 days agolisata.com
Lisata Therapeutics, Inc., a prominent player in the pharmaceutical preparation manufacturing industry, is headquartered in the United States. Founded in 2018, the company has rapidly established itself as a leader in developing innovative therapeutic solutions, particularly in the realm of oncology and rare diseases.
With a focus on advanced drug formulations and delivery systems, Lisata Therapeutics offers unique products that address unmet medical needs, setting them apart in a competitive market. The company’s commitment to research and development has led to significant milestones, including successful clinical trials and strategic partnerships that enhance its market position.
Lisata Therapeutics continues to drive advancements in pharmaceutical manufacturing, aiming to improve patient outcomes through its cutting-edge therapies and dedication to excellence in the healthcare sector.
23
DitchCarbon score
-17 vs industry average
Lisata Therapeutics, Inc.’s score of 23 is lower than 37% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Lisata Therapeutics, Inc.?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Very Low
Pharmaceutical Preparation Manufacturing is among the least carbon-intensive industries
Industry performance
0.243
02025
The Pharmaceutical Preparation Manufacturing industry has increased its overall emissions by 132% since 0
Emissions trajectory 2020 – 2025
Reported emissions
Scope 1
•••kg CO₂e
Scope 2
•••kg CO₂e
Scope 3
•••kg CO₂e
Total reported
•••kg CO₂e
Scope 3 accounts for ••• of total emissions.
Lisata Therapeutics, Inc.'s reported carbon emissions
Lisata Therapeutics, Inc., a pharmaceutical preparation manufacturing company headquartered in the US, reported its carbon emissions for 2022 and 2021.
In 2022, the company reported total Scope 1 emissions of approximately 404,000 kg CO2e and Scope 2 emissions of about 282,600 kg CO2e, resulting in combined Scope 1 and 2 emissions of approximately 686,600 kg CO2e. Scope 3 emissions data was not disclosed for this period.
For 2021, Lisata Therapeutics, Inc. reported Scope 1 emissions amounting to approximately 533,000,000 kg CO2e. Data for Scope 2 and Scope 3 emissions were not available for 2021.
Lisata Therapeutics, Inc. has not publicly disclosed specific reduction targets or commitments to science-based initiatives such as SBTi (Science Based Targets initiative). The company's climate commitments, beyond reporting its direct emissions, are not detailed in the provided information.
Unlock detailed emission data
Access structured emission data, company specific factors and auditable source documents
Lisata Therapeutics, Inc.’s Climate Goals (2030 & 2050)
No climate goals have been disclosed for Lisata Therapeutics, Inc. yet.
Scope 3 top emissions categories
No scope 3 category breakdown has been disclosed yet.
Emissions comparison with industry peers
View similar organisationsCompanyCountryIndustryLast updatedScoreDetails
Lisata Therapeutics, Inc.14 days ago
23
Usage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn more